Bank of America Corp DE increased its stake in ESSA Pharma Inc. (NASDAQ:EPIX - Free Report) TSE: EPI by 10,153,775.0% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 812,310 shares of the company's stock after buying an additional 812,302 shares during the quarter. Bank of America Corp DE owned 1.83% of ESSA Pharma worth $1,454,000 at the end of the most recent quarter.
Several other institutional investors also recently added to or reduced their stakes in EPIX. Two Sigma Securities LLC bought a new stake in ESSA Pharma in the fourth quarter worth about $29,000. Lepercq Multi Asset Fund purchased a new stake in shares of ESSA Pharma during the 4th quarter worth approximately $54,000. XTX Topco Ltd bought a new stake in shares of ESSA Pharma in the 4th quarter worth approximately $67,000. Jane Street Group LLC bought a new stake in shares of ESSA Pharma in the 4th quarter worth approximately $82,000. Finally, Vazirani Asset Management LLC purchased a new position in ESSA Pharma in the fourth quarter valued at approximately $90,000. Institutional investors own 75.12% of the company's stock.
ESSA Pharma Price Performance
NASDAQ EPIX remained flat at $1.71 on Friday. The company's stock had a trading volume of 76,303 shares, compared to its average volume of 338,747. The stock's 50 day simple moving average is $1.67 and its two-hundred day simple moving average is $1.69. ESSA Pharma Inc. has a 1-year low of $1.40 and a 1-year high of $7.88. The company has a market cap of $75.91 million, a price-to-earnings ratio of -2.48 and a beta of 1.69.
ESSA Pharma (NASDAQ:EPIX - Get Free Report) TSE: EPI last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.14) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.05. On average, analysts forecast that ESSA Pharma Inc. will post -0.42 earnings per share for the current fiscal year.
About ESSA Pharma
(
Free Report)
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.
Recommended Stories
Before you consider ESSA Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ESSA Pharma wasn't on the list.
While ESSA Pharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
